LG H&H

051900 · KOSPI · ₩051900 · LG생활건강

₩259,000▲ ₩2,000 (0.78%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Analyst target price

Average target

₩330,000

Upside

+27.4%

Range ₩310,000 – ₩350,000 · 2 brokers (latest target within 6 months)

Buy 1

Consensus target vs price, 2 years

2026-09 310,0002026-10 310,000
Consensus targetShare price2024-11 – 2026-10

Broker reports

DateBrokerReportRatingTargetChangeUpsideSince publishRead
Sep 29Kyobo SecuritiesA Breather in Q3Buy₩310,000New+19.7%−7.5%Read ↗

Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.

Reported in the news

DateBrokerTargetChangeRatingSource
Oct 26Sangsangin Investment & Securities₩350,000Raised—Reported by Edaily
Oct 26Sangsangin Investment & Securities₩350,000Raised—Reported by Edaily

Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.

AI summary of public information

An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.

LG H&H remains loss-making on a trailing basis after a weak 2025, with shares well below their 52-week high.

LG H&H, a Korean cosmetics, household goods and beverage group, reported a trailing twelve-month net loss of ₩75.5B on ₩6.29T revenue through H1 2026, with a thin 2.9% operating margin. Its 2025 full-year net loss of ₩100.1B followed profits in 2024 and 2023, and revenue has fallen for several years. The shares closed at ₩257,500, about 23% below their 52-week high of ₩335,500.

What stands out

  • Revenue has declined from ₩8.09T in 2021 to ₩6.29T trailing, while operating income fell from ₩1.29T to ₩184B over the same period.
  • The company holds ₩1.33T in cash against ₩77B in borrowings, and trailing free cash flow is ₩440B, so the balance sheet looks conservative.
  • Trailing P/B is 0.7 and EV/EBITDA is 6.9, but P/E is not meaningful because earnings are negative.
  • Foreign ownership rose to 31.8% from 29.6% over about 60 days, while 20-day flows show retail and foreign investors net sellers and institutions net buyers.
  • A news item dated 27 October 2026 cites a target price of ₩350,000 from one broker; this is a third-party view and not a forecast from this summary.

What to watch

  • The advance notice of earnings results was filed on 20 October 2026, so the full quarterly results are the next key test of whether the operating margin is recovering.
  • Filings from August and September 2026 include a rights offering (paid-in capital increase) decision and share acquisition and sale transactions in other companies; the data does not explain their size or purpose.
  • The data does not give details of the risks named in the filings, so check the full filings for risk disclosures.

Data as of Oct 26, 2026 · written 2d ago

This is not financial advice.

Also known as: LG H&H / LG생활건강 / 051900 / KRX:051900

Source: KRX statistical information